These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33815822)

  • 21. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
    Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
    Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
    Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
    Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
    Front Immunol; 2020; 11():851. PubMed ID: 32670260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avapritinib Approved for GIST Subgroup.
    Cancer Discov; 2020 Mar; 10(3):334. PubMed ID: 31974168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical activity of regorafenib in
    Grellety T; Kind M; Coindre JM; Italiano A
    Future Sci OA; 2015 Nov; 1(4):FSO33. PubMed ID: 28031906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New frontiers in the medical management of gastrointestinal stromal tumours.
    Mazzocca A; Napolitano A; Silletta M; Spalato Ceruso M; Santini D; Tonini G; Vincenzi B
    Ther Adv Med Oncol; 2019; 11():1758835919841946. PubMed ID: 31205499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
    Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report.
    Drom C; Schenheit K; Matzke M; Obeidat AZ; Molinaro J; Charlson J; Knight JM
    Brain Behav Immun Health; 2023 Feb; 27():100570. PubMed ID: 36578920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.
    Kollàr A; Maruzzo M; Messiou C; Cartwright E; Miah A; Martin-Liberal J; Thway K; McGrath E; Dunlop A; Khabra K; Seddon B; Dileo P; Linch M; Judson I; Benson C
    Clin Sarcoma Res; 2014; 4():17. PubMed ID: 25905001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fourth-line targeted drugs for the long-term treatment of patients with secondary gastrointestinal stromal tumors with multisite mutations: a case report.
    Zhang N; Wu X; Xu W; Chen L; Tu X
    Ann Palliat Med; 2023 Jan; 12(1):227-235. PubMed ID: 36747392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal Stromal Tumors.
    von Mehren M; Joensuu H
    J Clin Oncol; 2018 Jan; 36(2):136-143. PubMed ID: 29220298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avapritinib efficacy in primary hepatic neuroendocrine carcinoma with elevated PDGFRA expression: Insights from a PDX model study.
    Zhou Y; Song XL; Guo LB; Yu XR; Wang YC
    Biochem Biophys Res Commun; 2024 Dec; 736():150504. PubMed ID: 39121673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avapritinib (Ayvakit) for GIST.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):23-24. PubMed ID: 33647006
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
    Lim SY; Ferro-López L; Barquin E; Lindsay D; Thway K; Smith MJ; Benson C; Jones RL; Napolitano A
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment with avapritinib in patient with mucosal metastatic melanoma.
    Cocorocchio E; Pala L; Conforti F; Guerini-Rocco E; De Pas T; Ferrucci PF
    Ther Adv Med Oncol; 2020; 12():1758835920946158. PubMed ID: 32821296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.